Formulation Development
CANCER BIOMARKERS - Co-Analysis of CTCs & ctDNA: Gaining Multi-Dimensional Insights Into Cancer Heterogeneity
Yoon-Tae Kang, PhD, Abiodun Bodunrin, PhD, and Joby Chesnick, PhD, MBA, believe co-analysis of CTC abundance and phenotypic changes together with ctDNA concentration could allow for real-time monitoring of disease progression and reoccurrence, while genetic and epigenetic changes in CTCs and ctDNA mutations over time could provide valuable insights into the effectiveness of therapeutic interventions, as the presence of different somatic mutations may indicate cancer susceptibility or resistance to certain treatments.
Aragen Operationalizes First Phase of its Biologics Manufacturing Facility in India
Aragen recently announced it has operationalized the first phase of its biologics manufacturing facility in Bangalore, India, through its 100% subsidiary, Aragen Biologics Pvt Ltd.…
Intravacc & Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
The companies will leverage their combined experience in the development of conjugate vaccines for their clients….
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion Into Autoimmune Diseases
Mustang Bio, Inc. recently announced its expansion into autoimmune diseases with MB-106, a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. MB-106 is being developed in…
Leading CDMO PCI Pharma Services Releases Inaugural Comprehensive ESG Report
PCI Pharma Services (PCI) has released its first Environmental, Social & Governance (ESG) Report. A detailed overview of PCI’s multifaceted sustainability journey, the report showcases…
Abzena Announces Major Investment in Bioconjugation & ADC Capabilities in Response to Increasing Industry Demand
Abzena recently announced a significant expansion of their Bristol, PA bioconjugate development and cGMP manufacturing site. The $5-million investment in expanded laboratory….
Vidac Pharma Receives Japanese Patent Office Notice of Allowance for Cancer Drug Candidate
Vidac Pharma Holdings Plc. recently announced it has received a Notice of Allowance from the Japanese Patent Office for the composition and methods of use…
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors With RAF or RAS Mutations
Immuneering Corporation recently announced the first patient has been dosed in its Phase 1/2a trial of IMM-6-415 to treat advanced solid tumors with RAF or…
Vector Pharma & Oncopeptides FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East & North Africa
Oncopeptides AB and Vector Pharma FZCO recently announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle….
Vaccinex Announces $1.5-Million Registered Direct Offering & Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Vaccinex, Inc. recently announced it has entered into definitive agreements with certain institutional investors for the purchase and sale of 193,000 shares of its common stock in a….
LIXTE's Lead Clinical Compound Can Force Cancer Cells to Give Up Their Cancer-Causing Properties
LIXTE Biotechnology Holdings, Inc. recently announced publication of preclinical data in the online journal, Cancer Discovery, showing its lead clinical compound, LB-100, can force cancer…
Vetter Earns Prestigious Honors Across All Core Categories in the 13th Annual CDMO Leadership Awards
Vetter once again earned the 2024 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service for big pharma,…
Intravacc Announces Positive Data of First in Human Intranasal OMV-Based Vaccine for SARS-CoV-2
Intravacc recently announced positive clinical data of a first in human (FIH) study of Avacc 10, an intranasal outer membrane vesicles (OMV) based booster vaccine…
Teva UK & Closed Loop Medicine Announce Strategic Partnership to Advance Development of Personalized Medicines
Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalized medicine. Under the agreement, Closed Loop Medicine and Teva UK will investigate….
Nanoscope Therapeutics Announces Positive Top-line Results From Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa
Nanoscope Therapeutics Inc. recently announced positive top-line results after the completion of the 2-year Phase 2b RESTORE randomized, controlled clinical trial of its lead program, MCO-010,…
Exothera Pledges to Fast-Track RNA Therapies With Expansion of World-First Continuous-Batch RNA Manufacturing Solution Into North America
Game-changing continuous-batch production of RNA service removes process development and scale-up steps through automation and significantly cuts clinical development time, while enhancing quality and yield….
Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy in Patients with Rare Inherited Retinal Disease LCA5
Opus Genetics recently announced the first cohort has completed dosing in its open-label, dose-escalation Phase 1/2 clinical trial evaluating the subretinal delivery of OPGx-LCA5, an…
Bio-Rad Launches Validated Antibodies for Rare Cell & Circulating Tumor Cell Enumeration
Bio-Rad Laboratories, Inc. recently announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration. Validated for use with Bio-Rad’s Celselect…
Verge Genomics & Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy
Verge Genomics and Ferrer recently announced a strategic collaboration to co-develop VRG50635, Verge’s lead drug candidate, for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis….
Imbria Pharmaceuticals Presents Results From IMPROVE-HCM Trial of Ninerafaxstat
Imbria Pharmaceuticals, Inc. recently announced the results from the Phase 2 IMPROVE-HCM clinical trial, evaluating ninerafaxstat, a novel cardiac mitotrope and partial fatty acid oxidation…
